NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,126.728262812403,4.716450631177394,12.266569373293223,1.08872311932265,8.95647120560566,126.723226955911,percent_activity,1.69897000433602,26.869413616817,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.01745690597845,1.01745690597845,0.969442525567637,10.199999809265137,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,3.08563410607327,8.429584237301604,21.213877585035213,1.32662005842076,0.122016065451132,2.85986524216955,log2_fold_induction,1.69897000433602,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.03251455080914,1.03251455080914,1.00439340735198,10.199999809265137,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,136.506344134523,4.715117450248716,21.39013161208714,1.33021345676542,9.65026114229828,118.529903731384,percent_activity,1.69897000433602,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.07047149061399,1.07047149061399,0.895355977423959,10.199999809265137,cell cycle
APR_HepG2_CellCycleArrest_24h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.02770986934028,1.458478343872151,82.17532360608014,1.91474142300688,0.070464527201123,0.856424972654219,log2_fold_induction,2,0.70464527201123,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.95741909004689,1.84080217178763,1.79449604977182,10.199999809265137,cell cycle
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,2.29973011073503,2.4800955148118216,55.22997835332492,1.74217487300761,0.0927274815425616,2.10740843190227,log2_fold_induction,2,0.927274815425616,,1.6999443138819,1.52856557546834,1.50552999876409,10.199999809265137,cell cycle
APR_HepG2_CellLoss_24h_dn,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.780274314183844,1.178623412344048,50.66637644732416,1.7047198455734,0.066202173316075,0.740387158006228,log2_fold_induction,2,0.66202173316075,"[""Borderline active"",""Borderline active""]",1.87900333528815,1.5959923272122,1.48240030597005,10.199999809265137,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.86871839513006,2.1058844343493424,52.43008409954252,1.71958055433661,0.0887379366431112,1.77810506976425,log2_fold_induction,2,0.887379366431112,,1.71009741356478,1.55044756865388,1.51255084072644,10.199999809265137,cell cycle
ATG_Ahr_CIS_up,"Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ahr_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001612.1, , , ,"[131,21,57,310,41,150,57,131,21,41,150,310]",[165],Active,4.3047351438887125,4.345247010286112,5.479062248966094,0.7387062345885528,0.19813534805724511,4.518734899611112,log2_fold_induction,2,0.9906767402862255,,0.5682264821280275,0.4801626816866823,0.42850356143812623,10.199999809265137,dna binding
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1", , , ,,,Active,1.6099521821010634,2.684174546225883,16.0670625788065,1.2059364852000498,0.11995882938125292,1.3361620393330798,log2_fold_induction,1.47712125471966,0.5997941469062646,,1.116262482809302,0.9917274530792438,0.8279522921268772,10.199999809265137,dna binding
ATG_AP_2_CIS_dn,ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003211.1|NP_003212.2|NP_758438.2", , , ,,,Active,0.326208402716255,1.0225911448071276,17.68400734704153,1.247580686666936,0.06380035742980772,0.3824358536135948,log2_fold_induction,1.47712125471966,0.3190017871490386,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.4533384073516356,1.266609543973276,1.128300372635925,10.199999809265137,dna binding
ATG_BRE_CIS_up,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",NP_005891.1, , , ,,,Active,3.521964283494026,3.845713398566532,17.121855703810464,1.2335508326687963,0.183163117917566,2.96130945912234,log2_fold_induction,1.47712125471966,0.91581558958783,,1.1107752579552244,1.0353655404516908,0.9756028953898325,10.199999809265137,dna binding
ATG_C_EBP_CIS_up,"Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_C_EBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005185.2, , , ,,,Active,0.7517388421498282,1.5043090819310296,12.762255247261322,1.1059274263362529,0.09994473226005482,0.7991417373525207,log2_fold_induction,1.47712125471966,0.4997236613002741,,1.1430903277267725,1.0836567210454613,0.9866471124896018,10.199999809265137,dna binding
ATG_CRE_CIS_up,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006359.3, , , ,,,Active,1.4683748352992887,2.0099816197348064,8.877068903422778,0.9482695908682599,0.14610828486013952,1.5765642522352965,log2_fold_induction,2,0.7305414243006976,,0.9467862396155285,0.8206657028918721,0.620116914649916,10.199999809265137,dna binding
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2", , , ,,,Active,0.7780711483900735,1.3154187816939462,26.805575198456566,1.428225130823981,0.11830014277097414,0.777987745479341,log2_fold_induction,2,0.5915007138548707,,1.4908641875618673,1.4186739948765257,1.3089448162289377,10.199999809265137,nuclear receptor
ATG_DR5_CIS_up,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000955.1|NP_001277145.1|NP_000957.1", , , ,,,Active,0.9672632761188089,1.6296176606007409,13.179695856566601,1.119905388305116,0.11871045577184501,0.9662418754559208,log2_fold_induction,1.47712125471966,0.593552278859225,,1.1450207999771047,1.0905897682860237,1.0006249590170233,10.199999809265137,nuclear receptor
ATG_E2F_CIS_dn,ATG_E2F_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005216.1, , , ,,,Active,0.5929458343770536,1.2322944316620175,4.849538761354118,0.6857004349065259,0.0962344418902124,0.4941215287226479,log2_fold_induction,1,0.481172209451062,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0.9501888987789091,0.6762015860980984,0.28759068424814194,10.199999809265137,dna binding
ATG_E_Box_CIS_up,"Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_E_Box_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_009053.1, , , ,,,Active,0.6793982738593007,1.4382211145015615,36.57752739672731,1.5632143442718465,0.09447758303767596,0.679180384319884,log2_fold_induction,2,0.4723879151883798,"[""Only highest conc above baseline, active""]",1.6080030170334527,1.5450632902050048,1.4439331380439782,10.199999809265137,dna binding
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1, , , ,,,Active,2.4389295864799503,3.4958245676019173,9.974744518785439,0.9989017810001267,0.13953386614895374,2.463076143303028,log2_fold_induction,2,0.6976693307447688,,0.7720663103214859,0.6085090224281262,0.4539662585927644,10.199999809265137,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.9614412532396996,1.7748140277971587,11.252877042203965,1.0512635734528015,0.22103062321117403,1.690570530386454,log2_fold_induction,1.47712125471966,1.10515311605587,,1.1108080243693519,0.8944428240171698,0.5384607630892512,10.199999809265137,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.4734677055178746,2.9159647286427117,15.26527764972549,1.1837047077926948,0.10106210757931403,1.2100704410870302,log2_fold_induction,1.47712125471966,0.5053105378965701,,1.0586196839033883,0.9238757240587506,0.7610179991239236,10.199999809265137,nuclear receptor
ATG_Ets_CIS_dn,ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005229.1, , , ,,,Active,0.5614933117402314,1.549736332044602,19.248219518485552,1.2843905629843042,0.07246307647694375,0.554225018340043,log2_fold_induction,2,0.3623153823847187,"[""Less than 50% efficacy""]",1.38837513662598,1.204574265152621,0.9025233467324947,10.199999809265137,dna binding
ATG_FoxO_CIS_dn,ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_002006.2|NP_001446.1", , , ,,,Active,0.6585508007997516,1.398245822501298,30.375711196220102,1.4825264550007091,0.09419671279570589,0.6585071584669544,log2_fold_induction,2,0.4709835639785295,,1.532511162877631,1.467027159646636,1.36323752248326,10.199999809265137,dna binding
ATG_FXR_TRANS_up,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,1.1027451004627202,1.3312265659824114,38.78605910210376,1.5886756548989216,0.16567354177595192,0.9189542504305334,log2_fold_induction,2,0.8283677088797596,"[""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.9786944237926627,1.5188597636595234,0.8131140723408223,10.199999809265137,nuclear receptor
ATG_GLI_CIS_up,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005260.1, , , ,,,Active,0.45707064467597547,1.188961642738673,32.40530630259909,1.5106161308624573,0.07688568381788191,0.4570333474991109,log2_fold_induction,2,0.38442841908940956,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.6010700853116089,1.511624168101056,1.3913349449614096,10.199999809265137,dna binding
ATG_HIF1a_CIS_up,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001521.1, , , ,"[122,123,220,150,122,123,220,150]",[801],Active,1.7340847995098303,2.265338272651824,17.66334192094128,1.2470728759411007,0.15309720587379613,1.3151521446843488,log2_fold_induction,1,0.7654860293689807,,1.0310464041166925,0.3099948720140884,-0.7698375111193676,10.199999809265137,dna binding
ATG_HNF6_CIS_up,"Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HNF6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is homeobox protein.",NP_004489.1, , , ,,,Active,0.6579761383192716,1.831897311850927,6.336979003663584,0.8018822681780797,0.07183548270557376,0.5483134490254546,log2_fold_induction,1,0.3591774135278688,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active""]",0.8247108788168378,0.7126521419191978,0.5293443643938447,10.199999809265137,dna binding
ATG_HSE_CIS_up,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.",NP_005517.1, , , ,,,Active,0.6180337514837825,1.3012458077177078,27.561316012117018,1.440299950650512,0.09499108436211133,0.6179555985400379,log2_fold_induction,2,0.47495542181055667,,1.5054348269996791,1.4318350718426147,1.3210196318049274,10.199999809265137,dna binding
ATG_ISRE_CIS_dn,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002189.1, , , ,,,Active,2.2940879942943164,3.244711393936768,41.24106686808409,1.6153298915515557,0.14140474857524557,1.9117399952699137,log2_fold_induction,2,0.7070237428762278,,1.413168408715075,1.2444513651427094,1.065976890153111,10.199999809265137,dna binding
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2, , , ,,,Active,7.083351024850195,11.777475440864777,34.31599931683518,1.5354966505082843,0.12028640705584168,5.902792520711588,log2_fold_induction,2,0.6014320352792084,,0.7810919690090171,0.607435311210392,0.8382829608476471,10.199999809265137,dna binding
ATG_Myc_CIS_up,"Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myc_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_002458.2, , , ,,,Active,1.397917491253795,2.866198001797301,81.78067910813124,1.9126507126219543,0.09754507472109084,1.1649312441514126,log2_fold_induction,2,0.4877253736054542,,1.878780957932064,1.8405073028658594,1.7933702591990237,10.199999809265137,dna binding
ATG_NFI_CIS_up,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.",NP_001128145.1, , , ,,,Active,0.8986535899800745,2.133152333843236,24.47932556292954,1.3887994482638422,0.08425592262892893,0.8716087597906509,log2_fold_induction,2,0.4212796131446447,,1.3666637754617827,1.2226710670616896,0.9997137539550732,10.199999809265137,dna binding
ATG_NF_kB_CIS_up,"Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NF_kB_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.",NP_068810.3, , , ,,,Active,1.037236256034201,1.6204451160376487,8.074346191983174,0.9071073660855381,0.12801868397375604,1.2363766507721514,log2_fold_induction,2,0.6400934198687802,,0.9330194448096151,0.8782775659443809,0.7878270523680001,10.199999809265137,dna binding
ATG_NRF1_CIS_dn,ATG_NRF1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005002.3, , , ,,,Active,0.6590467899042418,1.6391549133468626,10.019198607879307,1.0008329855936424,0.08041299629924369,0.5492282889879432,log2_fold_induction,1.47712125471966,0.40206498149621844,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.025183902579696,0.9709534372956398,0.8812989676369384,10.199999809265137,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2, , , ,"[61,61]",[478],Active,1.7327024838245022,2.2311720421667625,9.513171329085067,0.9783253183178858,0.15531769411576343,1.9670219604946007,log2_fold_induction,1.47712125471966,0.7765884705788172,,0.9421537273948892,0.8043738648727282,0.5961624599560367,10.199999809265137,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3, , , ,,,Active,2.732494685088999,4.032071023997018,10.117233546725972,1.005061775385284,0.13553802345377633,2.658680072142541,log2_fold_induction,2,0.6776901172688816,,0.7418413388194329,0.5912187486124039,0.4836675412566772,10.199999809265137,dna binding
ATG_p53_CIS_up,"Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_p53_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,2.147496264392207,3.3596021145362656,45.077650428629696,1.6539612713387166,0.12784229746138445,1.7895802203296292,log2_fold_induction,2,0.6392114873069222,,1.4626712221933795,1.3139563982566127,1.1643740611522646,10.199999809265137,dna binding
ATG_Pax6_CIS_up,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.",NP_000271.1, , , ,,,Active,2.456414949831051,3.870064777305545,12.000185319039517,1.0791879529155248,0.12694438419923712,2.358409985637059,log2_fold_induction,2,0.6347219209961856,,0.7765993166842879,0.5925492627969416,0.4485957402101961,10.199999809265137,dna binding
ATG_PBREM_CIS_up,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001070948.1, , , ,"[8,107,58,8,107,58]","[456,715]",Active,0.6793644218829736,1.4170576543960158,5.952581011632541,0.7747053146465219,0.09588380822409588,0.7300239847473622,log2_fold_induction,1.47712125471966,0.4794190411204794,,0.8362307022313821,0.7529818837810927,0.6201251755813515,10.199999809265137,nuclear receptor
ATG_PPARa_TRANS_up,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_005027.2, , , ,"[51,18,318,6,36,61,58,37,166,37,6,318,51,18,166,36,61,58]",,Active,1.9244259817541318,1.6631351558708316,7.610308458280088,0.8814022597947593,0.23142147827985585,1.8940651960252635,log2_fold_induction,1.47712125471966,1.1571073913992793,,0.9412735788353366,0.7980253778042496,0.5611532966125461,10.199999809265137,nuclear receptor
ATG_PPARd_TRANS_up,"Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARd_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_006229.1, , , ,"[36,36]",,Active,1.653395549180515,1.507202745893651,17.64327270077909,1.2465791467855496,0.2193992219938776,1.638086876782678,log2_fold_induction,2,1.096996109969388,,1.347506634735051,1.185111329079932,0.9199058520175447,10.199999809265137,nuclear receptor
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,"[72,36,58,34,163,34,36,58,72,163]",,Active,2.756916583566213,2.402614518948617,2.500117155654567,0.3979603602169025,0.2294930428350727,3.554608217881511,log2_fold_induction,1,1.1474652141753636,,0.316145756136868,0.13195040118252094,-0.13335759503069344,10.199999809265137,nuclear receptor
ATG_PPRE_CIS_up,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_005027.2|NP_006229.1|NP_056953.2", , , ,,,Active,3.2059595153193077,3.5805370566227035,2.4483943336466076,0.38888136573449406,0.1790770191521653,3.0896458173441443,log2_fold_induction,1.47712125471966,0.8953850957608266,,0.029108936428990095,-0.2194426888656914,-0.4449824277919884,10.199999809265137,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,1.7836411348715555,2.676512052262627,10.138786157711522,1.0059859632257864,0.13328100901796647,1.4437521477384916,log2_fold_induction,1.47712125471966,0.6664050450898323,,0.8773334970977655,0.6968719513137465,0.4589182369277621,10.199999809265137,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,1.7115703267174733,1.3288087977357042,3.7985851573512734,0.5796218669396452,0.2576097222766731,2.2823997307007233,log2_fold_induction,1,1.2880486113833656,,0.6400039383951425,0.5690640724028334,0.4603415530574888,10.199999809265137,nuclear receptor
ATG_RARg_TRANS_up,"Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000957.1, , , ,,,Active,1.702242573050443,1.4726254030251162,4.099307120475971,0.6127104569189464,0.23118473571807732,1.4185354776855235,log2_fold_induction,1,1.1559236785903866,"[""Hit-call potentially confounded by overfitting""]",0.6568376816653696,0.5906556390587953,0.48333939443428464,10.199999809265137,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2", , , ,,,Active,2.3999999997930628,3.505312624098977,6.525552783784203,0.8146173069342413,0.13693500450105905,2,log2_fold_induction,1.47712125471966,0.6846750225052953,,0.6207224900028376,0.48160477619317643,0.350740801686023,10.199999809265137,nuclear receptor
ATG_Sox_CIS_up,"Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sox_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.",NP_005977.2, , , ,,,Active,0.669956294143591,1.5273327445908544,21.00643005127798,1.322352252274314,0.08772892436389956,0.6598204904171503,log2_fold_induction,2,0.4386446218194978,,1.43518207637438,1.245586574368244,0.9349427436230207,10.199999809265137,dna binding
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2, , , ,"[148,148]",,Active,1.1477951907571067,2.1846262375844825,18.369708554213073,1.264102266033565,0.10507931938290839,1.132447885144701,log2_fold_induction,2,0.525396596914542,,1.2320756271607225,1.0805223906639876,0.8487635782999119,10.199999809265137,dna binding
ATG_SREBP_CIS_up,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_004167.3, , , ,"[62,61,58,34,34,62,61,58]",,Active,0.7397934844621685,2.0360795031471732,47.587989849067235,1.6774973602747891,0.07266842805682862,0.6067433450498306,log2_fold_induction,2,0.3633421402841431,"[""Only highest conc above baseline, active""]",1.6697650965997786,1.487104137636833,1.1981616012516767,10.199999809265137,dna binding
ATG_STAT3_CIS_dn,ATG_STAT3_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_644805.1, , , ,,,Active,0.7243152338910055,1.6515076806432412,0.14213052700102805,-0.8473126336542425,0.08771563612818246,0.6623996564193726,log2_fold_induction,-0.397940008672038,0.4385781806409123,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",-0.824048057770187,-0.8777762000697354,-0.9666161181327159,10.199999809265137,dna binding
ATG_TCF_b_cat_CIS_dn,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003193.2|NP_001139746.1|NP_057353.1|NP_112573.1", , , ,,,Active,1.220432413862576,1.7667048379086456,9.754893596344848,0.989222536593447,0.13815917494257557,1.0170270115606532,log2_fold_induction,2,0.6907958747128778,"[""Hit-call potentially confounded by overfitting""]",1.159221051848715,0.5636659450337678,-0.416838692836321,10.199999809265137,dna binding
ATG_TGFb_CIS_up,"Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TGFb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.",P01137.2, , , ,,,Active,1.6477841001210176,2.123349006882364,7.351225688558779,0.8663597561452101,0.1552061479088074,1.3731534182425342,log2_fold_induction,1.47712125471966,0.776030739544037,"[""Hit-call potentially confounded by overfitting""]",0.8510682432011274,0.7438670573752114,0.5774971074615445,10.199999809265137,growth factor
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1, , , ,,,Active,2.7772659730684928,3.824511161823985,8.446794343002649,0.9266919203947432,0.1452350826317871,2.512136187383925,log2_fold_induction,1.47712125471966,0.7261754131589355,,0.6714993320436351,0.5134018828827367,0.3866780906472812,10.199999809265137,nuclear receptor
ATG_VDR_TRANS_up,"Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1, , , ,,,Active,0.9428119433841631,1.107451598918406,8.605652735385618,0.934783816979087,0.17026693433915513,0.9390467887681391,log2_fold_induction,2,0.8513346716957757,"[""Borderline active""]",1.2167277132542074,0.9559580109733267,0.6570728047283136,10.199999809265137,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2, , , ,,,Active,2.2460107778345373,3.813169907990778,16.037025148705624,1.205123810249705,0.11780281666064009,2.16876574461747,log2_fold_induction,2,0.5890140833032005,,0.9317652775380083,0.7616227217002494,0.624418831561406,10.199999809265137,dna binding
BSK_3C_Eselectin_down,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.27265262245510163,3.443398987319679,20.000000000000004,1.3010299956639813,0.022749058062569997,0.218223325,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.8340418326508958,10.199999809265137,cell adhesion molecules
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.5516742618951773,6.967233902373349,20.000000000000004,1.3010299956639813,0.025758990402599997,0.5505298750000001,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.8466201408456212,10.199999809265137,cell adhesion molecules
BSK_3C_MCP1_down,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.37071287998609814,4.373505828196153,20.000000000000004,1.3010299956639813,0.028254440453399997,0.257715805,log10_fold_induction,1.30102999566398,0.08476332136019998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.8334943142059489,10.199999809265137,cytokine
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.41031830076381476,3.4934597272211,20.000000000000004,1.3010299956639813,0.0391510930713,0.40820612,log10_fold_induction,1.30102999566398,0.1174532792139,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.8959638031125684,10.199999809265137,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.30074986355840916,3.798246157650997,20.000000000000004,1.3010299956639813,0.02172150128694,0.321767315,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.8947510270753944,10.199999809265137,cell cycle
BSK_3C_uPAR_down,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.37072977575458854,3.16207374084313,20.000000000000004,1.3010299956639813,0.0390808697223,0.28699712499999996,log10_fold_induction,1.30102999566398,0.1172426091669,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.7697179418237763,10.199999809265137,cytokine
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.13303115998588105,1.680084194505696,20.000000000000004,1.3010299956639813,0.0189344513925,0.10538427,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.4988090780534016,10.199999809265137,cell adhesion molecules
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1, , , ,,,Active,0.2591337330588381,3.1861802461012596,20.000000000000004,1.3010299956639813,0.027110177186399995,0.20599378000000002,log10_fold_induction,1.30102999566398,0.08133053155919999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.9509170658608712,10.199999809265137,cytokine
BSK_4H_Pselectin_down,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_002996.2, , , ,,,Active,0.3025163759835713,2.467705058519093,20.000000000000004,1.3010299956639813,0.04086338910171,0.247035675,log10_fold_induction,1.30102999566398,0.12259016730513,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.4261477894598851,10.199999809265137,cell adhesion molecules
BSK_4H_SRB_down,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.4489905959908842,5.6704158926828665,7,0.8450980400142568,0.02048812375239,0.341503905,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.4677559151347258,10.199999809265137,cell cycle
BSK_4H_uPAR_down,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.20035324796566012,1.8124260966830557,20.000000000000004,1.3010299956639813,0.03684807679098,0.16164288500000001,log10_fold_induction,1.30102999566398,0.11054423037293999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,-0.13990519433450155,10.199999809265137,cytokine
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.17805473993899293,2.248698382845593,20.000000000000004,1.3010299956639813,0.0228833401839,0.14441461500000002,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.6875343105490133,10.199999809265137,cell adhesion molecules
BSK_BE3C_HLADR_down,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.4301057639459286,5.431914568346584,7,0.8450980400142568,0.025097172292079997,0.341387405,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.3802572941442355,10.199999809265137,cell adhesion molecules
BSK_BE3C_IL1a_down,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3, , , ,,,Active,0.16203503998023458,2.030040500885018,20.000000000000004,1.3010299956639813,0.026606208087899996,0.12794942199999998,log10_fold_induction,1.30102999566398,0.07981862426369998,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.8021693267389514,10.199999809265137,cytokine
BSK_BE3C_IP10_down,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.7466495999884336,8.920578786201643,2,0.3010299956639812,0.027899893713299997,0.60294015,log10_fold_induction,1.30102999566398,0.08369968113989999,,0.3010299956639812,0.3010299956639812,-0.10620045690790114,10.199999809265137,cytokine
BSK_BE3C_MIG_down,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,0.15775390798256533,1.9923140371860495,20.000000000000004,1.3010299956639813,0.0077791965661199985,0.119047243,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.709699491289539,10.199999809265137,cytokine
BSK_BE3C_PAI1_down,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1, , , ,,,Active,0.24671702700910267,2.205406421857869,2,0.3010299956639812,0.0372897295428,0.24984094,log10_fold_induction,1.30102999566398,0.11186918862840001,"[""Less than 50% efficacy""]",0.3010299956639812,0.3010299956639812,-0.524565345788853,10.199999809265137,cytokine
BSK_BE3C_SRB_down,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_BE3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.2528513508729793,3.193323716084208,7,0.8450980400142568,0.005817857605706999,0.221273765,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,-0.08359562211202831,10.199999809265137,cell cycle
BSK_BE3C_tPA_down,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_000921.1, , , ,,,Active,0.29060239871602744,2.1748597931524105,7,0.8450980400142568,0.04453963724175,0.254383245,log10_fold_induction,1.30102999566398,0.13361891172525,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,-0.47098040166935495,10.199999809265137,protease
BSK_BE3C_uPA_down,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1, , , ,,,Active,0.44394145493624465,5.407111919860445,2,0.3010299956639812,0.02736774958092,0.356699975,log10_fold_induction,1.30102999566398,0.08210324874276,"[""Less than 50% efficacy""]",0.3010299956639812,0.3010299956639812,-0.14751328689530463,10.199999809265137,protease
BSK_BE3C_uPAR_down,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.40700787596178406,3.5787613378844263,7,0.8450980400142568,0.0379095667965,0.32259482500000003,log10_fold_induction,1.30102999566398,0.11372870038949999,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.16313951352261302,10.199999809265137,cytokine
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1, , , ,,,Active,0.21224419550559373,1.4994969393093045,7,0.8450980400142568,0.047181200117099996,0.22100035,log10_fold_induction,0.845098040014257,0.14154360035129998,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.19940336335884387,10.199999809265137,cell adhesion molecules
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.672802679821561,8.317915294487412,7,0.8450980400142568,0.0269619913164,0.46310637,log10_fold_induction,1.30102999566398,0.0808859739492,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.6170820656333609,10.199999809265137,cytokine
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.1541522504296402,1.441644945542553,20.000000000000004,1.3010299956639813,0.0356426758443,0.15413891000000002,log10_fold_induction,1.30102999566398,0.10692802753289998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.6904876375644804,10.199999809265137,cytokine
BSK_hDFCGF_MIG_down,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,0.15877963287229468,2.005268176466864,7,0.8450980400142568,0.015977820005069997,0.138522915,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,-0.05778564824506782,10.199999809265137,cytokine
BSK_hDFCGF_PAI1_down,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1, , , ,,,Active,0.7185989999956788,4.338375195393973,7,0.8450980400142568,0.055212605920499994,0.538412965,log10_fold_induction,1.30102999566398,0.1656378177615,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.5094490431026987,10.199999809265137,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.1384883282647609,8.401905815915258,2,0.3010299956639812,0.0451678604517,1.1005592,log10_fold_induction,1.30102999566398,0.1355035813551,,0.3010299956639812,0.3010299956639812,-0.14063494640864932,10.199999809265137,cell cycle
BSK_hDFCGF_SRB_down,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.31745621374066435,4.009234883089934,7,0.8450980400142568,0.024374730148650003,0.31735557999999997,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.7488367446744904,10.199999809265137,cell cycle
BSK_hDFCGF_VCAM1_down,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.24508475149369244,1.7345057602672647,20.000000000000004,1.3010299956639813,0.04709982465089999,0.224021625,log10_fold_induction,1.30102999566398,0.14129947395269998,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.25404557862366917,10.199999809265137,cell adhesion molecules
BSK_KF3CT_ICAM1_down,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2, , , ,,,Active,0.16235999960777595,2.0504855342908086,20.000000000000004,1.3010299956639813,0.02073805097175,0.120284172,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.6627914086452271,10.199999809265137,cell adhesion molecules
BSK_KF3CT_IP10_down,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.4864874395749632,6.143973022126446,20.000000000000004,1.3010299956639813,0.0138351257877,0.3708108,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.7553352516588984,10.199999809265137,cytokine
BSK_KF3CT_MMP9_down,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",AAM97934.1, , , ,,,Active,0.5737531559043629,6.854606190197933,7,0.8450980400142568,0.027901099882530003,0.45665595000000003,log10_fold_induction,1.30102999566398,0.08370329964759,"[""Less than 50% efficacy""]",0.8450980400142568,0.8450980400142568,0.2553222406933545,10.199999809265137,protease
BSK_KF3CT_SRB_down,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.1723559999815048,2.176727553363312,20.000000000000004,1.3010299956639813,0.00501083847705,0.136817135,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.17540002054188886,10.199999809265137,cell cycle
BSK_KF3CT_TIMP2_down,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",, , , ,,,Active,0.15322828798717392,1.666766761757713,20.000000000000004,1.3010299956639813,0.030643817220029995,0.121981162,log10_fold_induction,1.30102999566398,0.09193145166008998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,-1.2099298648484424,10.199999809265137,protease inhibitor
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.2911321919591293,2.1092156273708853,20.000000000000004,1.3010299956639813,0.0460095510042,0.23670338,log10_fold_induction,1.30102999566398,0.13802865301259998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.5355835213423561,10.199999809265137,cytokine
BSK_LPS_Eselectin_down,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.12159131985822544,1.53560755769229,20.000000000000004,1.3010299956639813,0.0245760564798,0.09071185000000001,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",1.3010299956639813,1.3010299956639813,0.3063503351060335,10.199999809265137,cell adhesion molecules
BSK_LPS_MCP1_down,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.33739929593401347,3.7625462940068566,2,0.3010299956639812,0.029891042711459998,0.23862831499999998,log10_fold_induction,1.30102999566398,0.08967312813438,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",0.3010299956639812,0.3010299956639812,-0.9003336749241062,10.199999809265137,cytokine
BSK_LPS_MCSF_down,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.271601279915471,2.6061868677228275,20.000000000000004,1.3010299956639813,0.0347380155633,0.20914209,log10_fold_induction,1.30102999566398,0.1042140466899,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,-0.11569590504797467,10.199999809265137,cytokine
BSK_LPS_SRB_down,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.24623417286751229,3.1097537000037967,20.000000000000004,1.3010299956639813,0.018219059086199998,0.245475395,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.867847105889652,10.199999809265137,cell cycle
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.2601521975665712,3.2855279570884566,20.000000000000004,1.3010299956639813,0.0224178208338,0.191263145,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.7054684671939627,10.199999809265137,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2, , , ,,,Active,0.3027720822222434,3.8237852690539413,20.000000000000004,1.3010299956639813,0.0243080164845,0.241171915,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.9623480919901874,10.199999809265137,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.5916850799146777,5.934741800532887,20.000000000000004,1.3010299956639813,0.0332328459435,0.43988107,log10_fold_induction,1.30102999566398,0.09969853783049999,"[""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.6166018609635628,10.199999809265137,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1, , , ,,,Active,0.4274869199264983,4.037501966820605,20.000000000000004,1.3010299956639813,0.03529302057225,0.32788057,log10_fold_induction,1.30102999566398,0.10587906171674999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.655949383265882,10.199999809265137,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.27661076393996975,2.4104155244897365,20.000000000000004,1.3010299956639813,0.038252154885,0.17331488,log10_fold_induction,1.30102999566398,0.114756464655,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.5209244971529156,10.199999809265137,cell adhesion molecules
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.2469953999916772,2.594618791307768,20.000000000000004,1.3010299956639813,0.031731751991099996,0.20489125,log10_fold_induction,1.30102999566398,0.09519525597329999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.6609425104959651,10.199999809265137,cytokine
BSK_SAg_PBMCCytotoxicity_up,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.1161862692457634,1.4673458052918404,20.000000000000004,1.3010299956639813,0.0217234984974,0.11606071500000001,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,0.8111014166756796,10.199999809265137,cell cycle
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.3142531493339237,2.625783804050836,20.000000000000004,1.3010299956639813,0.0398932500141,0.29781221,log10_fold_induction,1.30102999566398,0.1196797500423,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.3010299956639813,1.3010299956639813,1.0163978429015328,10.199999809265137,cell cycle
BSK_SAg_SRB_down,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.2203797101585593,2.783231145743885,20.000000000000004,1.3010299956639813,0.017346765986949,0.21999911,log10_fold_induction,1.30102999566398,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3010299956639813,1.3010299956639813,0.8364409623790248,10.199999809265137,cell cycle
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,98.8878225195751,4.944391125978755,0.6227836604061286,-0.205662790273062,1.53481347591287,99.5188160519181,percent_activity,0,20,,-0.280160286910047,-0.369570077096342,-0.324943103959694,10.199999809265137,malformation
CCTE_Simmons_AUR_TPO_dn,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",P14650.1, , , ,,,Active,37.1362622539055,1.856813112695275,12.431768983412402,1.09453293114141,5.55295187687267,29.9553803295717,percent_activity,1.60205999132796,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.20038572810463,0.953167810875057,-0.410509170779963,10.199999809265137,oxidoreductase
CCTE_Simmons_MITO_basal_resp_rate_OCR_up,"Data from the assay component CCTE_Simmons_MITO_basal_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_basal_resp_rate_OCR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of basal respiration for gain-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.898758843257298,4.49379421628649,2.2248471201366313,0.347300173895756,0.0152478290084298,0.688169680850877,fold_induction,0.698970004336019,0.2,"[""Noisy data"",""Noisy data""]",-0.0843867507243095,-0.662300446872118,-0.410910842249238,10.21030044555664,mitochondria
CCTE_Simmons_MITO_basal_resp_rate_OCR_up,"Data from the assay component CCTE_Simmons_MITO_basal_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_basal_resp_rate_OCR_up, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of basal respiration for gain-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.898758843257298,4.49379421628649,2.2248471201366313,0.347300173895756,0.0152478290084298,0.688169680850877,fold_induction,0.698970004336019,0.2,"[""Noisy data"",""Noisy data""]",-0.0843867507243095,-0.662300446872118,-0.410910842249238,10.21030044555664,mitochondria
CCTE_Simmons_MITO_inhib_resp_rate_OCR_dn,"Data from the assay component CCTE_Simmons_MITO_inhib_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_inhib_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of inhibited respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.312745904466162,1.0424863482205402,22.874237896409536,1.35934663354078,0.0522646889639235,0.305580781679008,fold change,1.69897000433602,0.3,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.5309226513908,1.35963920739102,1.23999175201602,10.21030044555664,mitochondria
CCTE_Simmons_MITO_inhib_resp_rate_OCR_dn,"Data from the assay component CCTE_Simmons_MITO_inhib_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_inhib_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of inhibited respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.312745904466162,1.0424863482205402,22.874237896409536,1.35934663354078,0.0522646889639235,0.305580781679008,fold change,1.69897000433602,0.3,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.5309226513908,1.35963920739102,1.23999175201602,10.21030044555664,mitochondria
CCTE_Simmons_MITO_max_resp_rate_OCR_dn,"Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.983382295366227,4.916911476831134,23.895602226242787,1.37831798025285,0.0389563523656356,0.803364587430287,fold change,1.69897000433602,0.2,,1.08208694809216,0.943633562767819,0.901584326502461,10.21030044555664,mitochondria
CCTE_Simmons_MITO_max_resp_rate_OCR_dn,"Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.983382295366227,4.916911476831134,23.895602226242787,1.37831798025285,0.0389563523656356,0.803364587430287,fold change,1.69897000433602,0.2,,1.08208694809216,0.943633562767819,0.901584326502461,10.21030044555664,mitochondria
CCTE_Simmons_MITO_viability,"Data from the assay component CCTE_Simmons_MITO_viability was analyzed at the endpoint, CCTE_Simmons_MITO_viability, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,24.7111335578712,1.23555667789356,2.521708638135106,0.401694906122866,6.74146038501161,26.7894527545808,percent activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.525646620679425,0.5307867710156,0.213322342750878,10.21030044555664,cell cycle
CCTE_Simmons_MITO_viability,"Data from the assay component CCTE_Simmons_MITO_viability was analyzed at the endpoint, CCTE_Simmons_MITO_viability, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,24.7111335578712,1.23555667789356,2.521708638135106,0.401694906122866,6.74146038501161,26.7894527545808,percent activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.525646620679425,0.5307867710156,0.213322342750878,10.21030044555664,cell cycle
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2, , , ,"[27,27]",,Active,7.62172365280014,13.57984221271386,3.277696077820443,0.515568681435596,0.187084246719363,7.8208979125161,log2_fold_induction,1.30102999566398,0.561252740158089,,0.19747413405194,0.19747413405194,0.239542323077111,10.186666488647461,transporter
LTEA_HepaRG_ABCB1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000918.2, , , ,,,Active,4.17265781869237,10.998184677943405,3.4117351680520414,0.532975312203144,0.126465046759354,3.4510189606855,log2_fold_induction,0.698970004336019,0.379395140278062,,0.324526993228131,0.324526993228131,0.334049380783206,10.186666488647461,transporter
LTEA_HepaRG_ABCC2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000383.1, , , ,,,Active,3.93289263979582,9.164065390876612,2.5368198207662767,0.404289622276598,0.143054873284778,3.26383220643497,log2_fold_induction,0.698970004336019,0.429164619854334,,0.290299245654438,0.290299245654438,0.285007145321124,10.186666488647461,transporter
LTEA_HepaRG_ABCC3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003777.2, , , ,,,Active,1.89629886495746,3.7870346298576636,2.723000328696695,0.435047693764185,0.166911497631656,1.44644909868207,log2_fold_induction,0.698970004336019,0.500734492894968,,0.379404098987503,0.379404098987503,0.315765666960404,10.186666488647461,transporter
LTEA_HepaRG_ABCG2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004818.2, , , ,,,Active,2.81600236670124,4.672813880632764,2.636786804963996,0.421075016721488,0.200878417062049,2.79848259778097,log2_fold_induction,0.698970004336019,0.602635251186147,,0.349816463405414,0.349816463405414,0.300724449317561,10.186666488647461,transporter
LTEA_HepaRG_ACLY_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001087.2, , , ,,,Active,1.39311835902168,3.9792381026674337,2.881561350318851,0.459627870428325,0.116698919330631,1.11315846044516,log2_fold_induction,0.698970004336019,0.350096757991893,,0.327622113532671,0.327622113532671,0.193936835864902,10.186666488647461,lyase
LTEA_HepaRG_ACOX1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_009223.2, , , ,,,Active,3.40783868131471,8.425722194592392,3.285216339098838,0.516563974134218,0.134818855982927,3.43741904048763,log2_fold_induction,1.69897000433602,0.404456567948781,,0.276757356653321,0.276757356653321,0.253759910126483,10.186666488647461,oxidase
LTEA_HepaRG_ADK_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006712.2, , , ,,,Active,5.88140739101818,11.808800470548643,5.2467471293312276,0.719890133574654,0.166017635341442,4.73819956566155,log2_fold_induction,1.30102999566398,0.498052906024326,,0.587934808665919,0.587934808665919,0.598086959884619,10.186666488647461,kinase
LTEA_HepaRG_ALPP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001623.3, , , ,,,Active,4.58835289795405,4.572655578068339,5.479383545101866,0.738731701181441,0.33447762243899,4.58834654717156,log2_fold_induction,1.69897000433602,1.00343286731697,,0.669607771049201,0.669607771049201,0.619451324731558,10.186666488647461,phosphatase
LTEA_HepaRG_APOA5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_443200.2, , , ,,,Active,4.39119665555209,5.133967450125133,3.0675709125441757,0.486794611030881,0.285107420866427,5.64688772099436,log2_fold_induction,0.698970004336019,0.855322262599281,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",0.40957423277972,0.40957423277972,0.367244146432432,10.186666488647461,apolipoprotein
LTEA_HepaRG_BCL2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000624.2, , , ,,,Active,2.97596167458717,6.26621281784306,2.49457896723459,0.396997256317459,0.15830729879421,2.49704868236307,log2_fold_induction,0.698970004336019,0.47492189638263,,0.305848650827726,0.305848650827726,0.276445535988381,10.186666488647461,cell cycle
LTEA_HepaRG_BCL2L11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_619527.1, , , ,,,Active,1.4734635470312,3.585993153993134,2.61075672157152,0.416766404798238,0.136964710914227,1.4650776627582,log2_fold_induction,0.698970004336019,0.410894132742681,,0.364835209151035,0.364835209151035,0.296670264898263,10.186666488647461,cell cycle
LTEA_HepaRG_BID_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001187.1, , , ,,,Active,5.77919325281073,8.280310082656303,4.895486174577132,0.689795828407054,0.232648020630518,5.77893767787477,log2_fold_induction,1.69897000433602,0.697944061891554,,0.486033381422927,0.486033381422927,0.464268000948151,10.186666488647461,cell cycle
LTEA_HepaRG_CASP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_116786.1, , , ,,,Active,3.10367595288572,6.746364768893267,4.214131499826913,0.624708083421619,0.153350535644343,2.53852906994732,log2_fold_induction,1.30102999566398,0.460051606933029,,0.336078034051877,0.336078034051877,0.262019734407799,10.186666488647461,protease
LTEA_HepaRG_CASP8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_203520.1, , , ,,,Active,3.60403419125127,8.374965372954419,6.987171012991227,0.844301372864981,0.143444739998166,3.31075435485525,log2_fold_induction,1.30102999566398,0.430334219994498,,0.472904878166811,0.472904878166811,0.435890834237223,10.186666488647461,protease
LTEA_HepaRG_CAT_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001743.1, , , ,,,Active,5.14347649141788,9.062744906441864,3.702412114270783,0.568484758282985,0.189180229776443,4.11820597473406,log2_fold_induction,1.30102999566398,0.567540689329329,,0.256318623750736,0.256318623750736,0.239871621568116,10.186666488647461,catalase
LTEA_HepaRG_CCND1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_444284.1, , , ,,,Active,3.15652469826793,8.050542024876638,2.6486257032278075,0.423020589286986,0.130696156379454,2.58866831277557,log2_fold_induction,0.698970004336019,0.392088469138362,,0.313369843446675,0.313369843446675,0.299664509735375,10.186666488647461,cell cycle
LTEA_HepaRG_CDKN1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000380.1, , , ,,,Active,0.664771292652212,1.7073232489370043,0.7049730108113816,-0.151827509221443,0.129788211471984,0.545610178012374,log2_fold_induction,1.30102999566398,0.389364634415952,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",0.0308233731189048,0.0308233731189048,-1.31083030727678,10.186666488647461,cell cycle
LTEA_HepaRG_CDKN1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000380.1, , , ,,,Active,1.12122388504113,2.8796243570579256,15.991638474049473,1.20389296304477,0.129788211471984,0.959060717737527,log2_fold_induction,1.30102999566398,0.389364634415952,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.1696339449037,1.1696339449037,1.08461217891788,10.186666488647461,cell cycle
LTEA_HepaRG_CFLAR_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003870.4, , , ,,,Active,1.35171416758228,3.187712987185441,2.219926146210838,0.346338526330536,0.141346285253843,1.4416125615802,log2_fold_induction,1.30102999566398,0.424038855761529,,0.303839730016355,0.303839730016355,0.227058203687663,10.186666488647461,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,3.24078787993538,3.5985535791999763,9.024864560593414,0.955440693012235,0.300193564683644,2.91311778426833,log2_fold_induction,1.69897000433602,0.900580694050932,,0.624192832077324,0.624192832077324,0.193283355079834,10.186666488647461,cyp
LTEA_HepaRG_CYP1A2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000752.2, , , ,"[131,131]",,Active,4.95969671640421,5.223522117767453,4.5496277983309925,0.657975868801539,0.316497604782422,4.44969978241198,log2_fold_induction,1.30102999566398,0.949492814347266,,0.511819635831734,0.511819635831734,0.435066944591468,10.186666488647461,cyp
LTEA_HepaRG_CYP2B6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000758.1, , , ,,,Active,10.4030940441936,13.799840932402889,4.143499772979795,0.61736731938495,0.251285361310856,8.48307128548814,log2_fold_induction,0.698970004336019,0.753856083932568,,0.478966747813311,0.478966747813311,0.498087005704596,10.186666488647461,cyp
LTEA_HepaRG_CYP2C19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000760.1, , , ,,,Active,7.66362477895759,13.66523883309122,4.291862136180503,0.632645763047482,0.186937207917646,7.64551334252026,log2_fold_induction,1.30102999566398,0.560811623752938,,0.356551687589072,0.356551687589072,0.39370371203995,10.186666488647461,cyp
LTEA_HepaRG_CYP2C8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000761.3, , , ,,,Active,7.73160999738059,11.942574406327605,4.331567448079811,0.636645081311687,0.215799646271804,7.73156830432776,log2_fold_induction,1.69897000433602,0.647398938815412,,0.431344496123596,0.431344496123596,0.448113787248827,10.186666488647461,cyp
LTEA_HepaRG_CYP2C9_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000762.2, , , ,,,Active,11.3091889967494,12.009389847157697,4.066504324618565,0.609221238496976,0.313898517206961,8.89392135621627,log2_fold_induction,1.30102999566398,0.941695551620883,,0.315831433551168,0.315831433551168,0.340479733583676,10.186666488647461,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1, , , ,,,Active,8.98272921834946,18.755927712764343,2.445159282766334,0.388307155227864,0.159642493756543,8.89026033477077,log2_fold_induction,0.698970004336019,0.478927481269629,,0.230998760409793,0.230998760409793,0.268155753108193,10.186666488647461,cyp
LTEA_HepaRG_CYP3A4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_059488.2, , , ,,,Active,12.3688961259853,10.423980171920851,4.5771891011345724,0.660598855158954,0.395526977922934,12.7647323936997,log2_fold_induction,1.30102999566398,1.1865809337688,,0.538819559665084,0.538819559665084,0.541318541446751,10.186666488647461,cyp
LTEA_HepaRG_CYP3A5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000768.1, , , ,,,Active,6.34223796161117,8.295604986621955,13.891178641484625,1.14273909640546,0.254843296413747,5.28254244555531,log2_fold_induction,1.69897000433602,0.764529889241241,,0.417345406696104,0.417345406696104,0.340708596868647,10.186666488647461,cyp
LTEA_HepaRG_CYP3A7_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000756.3, , , ,,,Active,4.875524077177,6.2821839988582555,4.269271203557282,0.630353744044352,0.258695812266514,3.8029987108266,log2_fold_induction,0.698970004336019,0.776087436799542,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.540002053300705,0.540002053300705,0.511073430255262,10.186666488647461,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2, , , ,,,Active,6.47629694253676,10.13161916824623,4.186220003885163,0.621822048647338,0.213072127136213,6.5297517006784,log2_fold_induction,1.30102999566398,0.639216381408639,,0.501753574276445,0.501753574276445,0.502541734482206,10.186666488647461,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2, , , ,,,Active,5.81647919782901,7.200919856106074,3.2923834727444032,0.517510412930813,0.269247045935707,6.10592389756297,log2_fold_induction,0.698970004336019,0.807741137807121,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.418209392022533,0.418209392022533,0.397936277292518,10.186666488647461,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2, , , ,,,Active,11.2025316795988,20.856604176385932,3.7642839797807515,0.575682379420352,0.179040518530855,11.198508094057,log2_fold_induction,1.30102999566398,0.537121555592565,,0.304352853435972,0.304352853435972,0.376196151980914,10.186666488647461,cyp
LTEA_HepaRG_DDIT3_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001181982.1, , , ,,,Active,3.46351761594677,6.0254594336518315,16.237910234404666,1.21053013623121,0.191604621140491,2.87980958636477,log2_fold_induction,1.30102999566398,0.574813863421473,,1.12288316411438,1.12288316411438,1.09124982165069,10.186666488647461,dna binding
LTEA_HepaRG_EGF_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001954.2, , , ,,,Active,5.21691444397863,9.014023217680883,51.521301179235294,1.71198682267136,0.192918460417901,3.32639159774053,log2_fold_induction,1.69897000433602,0.578755381253703,"[""Noisy data"",""Noisy data""]",1.29109964243907,1.29109964243907,1.26763413795026,10.186666488647461,growth factor
LTEA_HepaRG_EGR1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001955.1, , , ,,,Active,3.00498827987536,5.6913072451393365,2.604049095086425,0.415649167885451,0.175998714673843,2.44522509266972,log2_fold_induction,0.698970004336019,0.527996144021529,,0.331419825004427,0.331419825004427,0.295917374870267,10.186666488647461,dna binding
LTEA_HepaRG_EZR_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003370.2, , , ,,,Active,1.22983076109813,2.603738349504786,3.422860096990232,0.534389148525305,0.15744423287028,0.973239626001823,log2_fold_induction,1.30102999566398,0.47233269861084,,0.371397782246486,0.371397782246486,-0.22381601756348,10.186666488647461,membrane protein
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1, , , ,,,Active,11.7855272929267,24.42120185400764,3.5972175206625225,0.555966700027901,0.160864691309103,9.54946222545932,log2_fold_induction,1.30102999566398,0.482594073927309,,0.230572152235539,0.230572152235539,0.32925581414226,10.186666488647461,transporter
LTEA_HepaRG_FAS_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000034.1, , , ,,,Active,1.58510676682655,2.8415397849338153,5.023937497452481,0.701044227727479,0.185944580145241,1.28402832324229,log2_fold_induction,1.30102999566398,0.557833740435723,,0.434614714880477,0.434614714880477,-0.25769061916311,10.186666488647461,cytokine receptor
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4, , , ,"[58,34,34,58]",,Active,3.14195941322678,8.548719264685092,2.335944272313247,0.368462477774465,0.122511895873739,2.49133370885051,log2_fold_induction,0.698970004336019,0.367535687621217,,0.258317710201536,0.258317710201536,0.248735835579679,10.186666488647461,lyase
LTEA_HepaRG_FMO3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001002294.1, , , ,,,Active,7.55523760587991,17.328905483626254,4.783045802962687,0.679704539742695,0.145330155887393,6.1507345922887,log2_fold_induction,1.30102999566398,0.435990467662179,,0.290747865655107,0.290747865655107,0.373709381030123,10.186666488647461,oxidoreductase
LTEA_HepaRG_FOXO1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002006.2, , , ,,,Active,1.32613307687534,3.262184205057712,6.14996538434975,0.788872671315547,0.135505640139235,1.25003862863146,log2_fold_induction,1.30102999566398,0.406516920417705,,0.622116846251485,0.622116846251485,0.340035027046316,10.186666488647461,dna binding
LTEA_HepaRG_FOXO3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001446.1, , , ,,,Active,0.691990529529369,1.803856302684354,1.977293164733373,0.296071065058207,0.127872441668368,0.763875780438415,log2_fold_induction,0.698970004336019,0.383617325005104,,0.307923762610656,0.307923762610656,0.176790749309478,10.186666488647461,dna binding
LTEA_HepaRG_GADD45A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001915.1, , , ,,,Active,2.98870058583761,4.935219421893851,4.510483377608689,0.654223086662656,0.201862053831487,2.05365249873732,log2_fold_induction,0.698970004336019,0.605586161494461,"[""Hit-call potentially confounded by overfitting"",""Noisy data"",""Hit-call potentially confounded by overfitting"",""Noisy data""]",0.576398573013551,0.576398573013551,0.529404037149068,10.186666488647461,cell cycle
LTEA_HepaRG_GADD45B_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_056490.2, , , ,,,Active,4.47053317662409,10.656025471219076,20.84618458994305,1.31902657906213,0.139843671504558,3.71865130639821,log2_fold_induction,1.69897000433602,0.419531014513674,,0.777001345367753,0.777001345367753,0.793819066780349,10.186666488647461,mutagenicity response
LTEA_HepaRG_GADD45G_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006696.1, , , ,,,Active,1.44750897547209,3.0941128772263853,12.295627513635193,1.08975069808122,0.155942271975725,1.43435425595179,log2_fold_induction,1.69897000433602,0.467826815927175,"[""Noisy data"",""Noisy data""]",1.04962568660449,1.04962568660449,0.970470382756852,10.186666488647461,mutagenicity response
LTEA_HepaRG_GCLC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001489.1, , , ,,,Active,3.40738009790925,7.768445929002043,2.4701161408292482,0.392717373557423,0.146205994911991,2.79902481826982,log2_fold_induction,0.698970004336019,0.438617984735973,,0.287415791570038,0.287415791570038,0.271724500417528,10.186666488647461,ligase
LTEA_HepaRG_GSTA2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000837.3, , , ,,,Active,9.54726100328678,14.51290391800785,3.988434799723439,0.600802496888245,0.219282119719688,9.49715293972219,log2_fold_induction,1.30102999566398,0.657846359159064,,0.255428561990738,0.255428561990738,0.309340305860698,10.186666488647461,transferase
LTEA_HepaRG_GSTM3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000840.2, , , ,,,Active,2.885132085796,3.7017908271578603,3.6854231053726756,0.566487354279293,0.259796066328175,3.17580020685854,log2_fold_induction,1.69897000433602,0.779388198984525,,0.417026112664824,0.417026112664824,0.236076834169547,10.186666488647461,transferase
LTEA_HepaRG_HGF_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000592.3, , , ,,,Active,5.07390476066934,7.146809261935031,9.384133402407162,0.972394172969099,0.236651283797079,3.89349776816606,log2_fold_induction,1.30102999566398,0.709953851391237,,0.474048123638533,0.474048123638533,0.369410411765866,10.186666488647461,growth factor
LTEA_HepaRG_HIF1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001521.1, , , ,"[122,123,220,150,122,123,220,150]",[801],Active,1.30457693567413,3.3013958395568963,4.760875092403962,0.677686787357452,0.131719733013418,1.49599480830648,log2_fold_induction,1.69897000433602,0.395159199040254,,0.621697799521504,0.621697799521504,0.530094652508471,10.186666488647461,dna binding
LTEA_HepaRG_HMGCS2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005509.1, , , ,"[60,60]",,Active,11.481587809401,21.931848729372067,4.7503180422314095,0.676722687385327,0.174504027621778,11.4748223465203,log2_fold_induction,1.69897000433602,0.523512082865334,,0.259451774766523,0.259451774766523,0.375257397105381,10.186666488647461,lyase
LTEA_HepaRG_HSPA1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005337.2, , , ,,,Active,3.3174432356287,6.997991128496813,4.974654741501228,0.696762944566359,0.158018835916096,2.48541462276956,log2_fold_induction,1.30102999566398,0.474056507748288,,0.385090914591937,0.385090914591937,0.314489839769944,10.186666488647461,dna binding
LTEA_HepaRG_ICAM1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000192.2, , , ,,,Active,0.799745330351966,1.3976159274230389,2.026576976120848,0.306763104337084,0.190740368332464,0.648750772835755,log2_fold_induction,1.30102999566398,0.572221104997392,"[""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",0.608922676059157,0.608922676059157,-0.413105632491632,10.186666488647461,cell adhesion molecules
LTEA_HepaRG_ICAM1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000192.2, , , ,,,Active,0.923243874631019,1.6134390475430418,16.16179536891516,1.20848960368503,0.190740368332464,0.780078780761845,log2_fold_induction,1.30102999566398,0.572221104997392,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.23501818293931,1.23501818293931,1.08920926138349,10.186666488647461,cell adhesion molecules
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,4.22926530435186,8.688235151667001,5.212722055502951,0.717064568782873,0.162260237763032,3.21324984762943,log2_fold_induction,1.30102999566398,0.486780713289096,,0.382103051787496,0.382103051787496,0.356232666061826,10.186666488647461,growth factor
LTEA_HepaRG_IGFBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000587.1, , , ,,,Active,4.95682760734909,5.724415862836301,6.687818141944921,0.825284455067379,0.288636589078576,4.8836449425913,log2_fold_induction,1.69897000433602,0.865909767235728,,0.596202287097771,0.596202287097771,0.501119625865684,10.186666488647461,transporter
LTEA_HepaRG_IL6R_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000556.1, , , ,,,Active,1.97932667101148,5.054933503285916,9.474814796068443,0.976570729581365,0.130521114981027,1.53183928161923,log2_fold_induction,1.69897000433602,0.391563344943081,,-0.0836583181348736,-0.0836583181348736,-0.687479747638155,10.186666488647461,cytokine receptor
LTEA_HepaRG_IL6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000591.1, , , ,,,Active,5.54133201138306,6.919914324645424,15.564099567449004,1.19212400043133,0.266926812067961,5.41681283080885,log2_fold_induction,1.69897000433602,0.800780436203883,,0.952948170978016,0.952948170978016,0.896607767885247,10.186666488647461,cytokine
LTEA_HepaRG_KCNK1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002236.1, , , ,,,Active,2.08720797573247,2.9397236346019264,24.056977653735736,1.38124106478464,0.236667142353684,2.08128000282376,log2_fold_induction,1.69897000433602,0.710001427061052,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.34526602393329,1.34526602393329,1.26193568402301,10.186666488647461,ion channel
LTEA_HepaRG_KRT19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002267.2, , , ,,,Active,1.54375393179884,2.8498989027334374,5.563881929690825,0.745377905319322,0.180562420456175,1.54362794851238,log2_fold_induction,1.30102999566398,0.541687261368525,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",0.711980710751422,0.711980710751422,0.626084392456539,10.186666488647461,filaments
LTEA_HepaRG_LDH_cytotoxicity,LDH leakage activity as a measure of membrane integrity and cytotoxicity in the cells.,, , , ,,,Active,41.0067299931275,4.3003093355186435,6.37505247341697,0.804483763823114,0.9535762847205,41.12957042,percent_activity,1.30102999566398,9.535762847205,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.661669015678822,0.494655977403025,0.541676547243626,10.186666488647461,cell cycle
LTEA_HepaRG_LIPC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000227.2, , , ,,,Active,4.55303564157525,8.758276950819917,4.187130736809538,0.621916521289737,0.173285060031091,4.53910711829368,log2_fold_induction,1.30102999566398,0.519855180093273,,0.382113315141884,0.382113315141884,0.364735870762587,10.186666488647461,esterase
LTEA_HepaRG_LPL_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000228.1, , , ,,,Active,1.66747398655271,4.227983099840117,8.335511768058705,0.920932268977567,0.131463312189033,1.3772459429474,log2_fold_induction,1.69897000433602,0.394389936567099,,0.329899208643932,0.329899208643932,-0.187250551601147,10.186666488647461,esterase
LTEA_HepaRG_MIR122_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,6.56532340414605,6.111780493055951,3.595979138659592,0.555817163597536,0.358069328111801,7.765748768838,log2_fold_induction,1.30102999566398,1.0742079843354,,0.378763785240487,0.378763785240487,0.317377296862669,10.186666488647461,microrna
LTEA_HepaRG_MMP10_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002416.1, , , ,,,Active,8.17510125772698,3.70648129689208,29.373437694809663,1.46795477677539,0.735207744029526,6.67752021391206,log2_fold_induction,1.69897000433602,2.20562323208858,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.30944208797427,1.30944208797427,1.11814491019739,10.186666488647461,protease
LTEA_HepaRG_MMP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002413.1, , , ,,,Active,3.69056054042691,3.9290061072442204,14.081413422944149,1.14864624933571,0.313103826573539,2.95712424219931,log2_fold_induction,1.30102999566398,0.939311479720617,"[""Only one conc above baseline, active"",""Only one conc above baseline, active""]",1.08835143824637,1.08835143824637,1.02536925742521,10.186666488647461,protease
LTEA_HepaRG_MMP3_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002413.1, , , ,,,Active,1.90839092717763,2.0316912636320064,43.12391446331889,1.63471817594164,0.313103826573539,1.4634207151566,log2_fold_induction,1.30102999566398,0.939311479720617,"[""Noisy data"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Noisy data"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.63302445675597,1.63302445675597,1.51543785753944,10.186666488647461,protease
LTEA_HepaRG_MYC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002458.2, , , ,,,Active,3.2711839995765,6.961795110568271,19.894679486633464,1.29873694683462,0.15662550379718,3.2691294725522,log2_fold_induction,1.69897000433602,0.46987651139154,,1.20181481505063,1.20181481505063,1.17945663196282,10.186666488647461,dna binding
LTEA_HepaRG_NFE2L2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006155.2, , , ,"[61,61]",[478],Active,1.90397442858101,6.19557253709753,3.335846626068169,0.523206074644506,0.102437367823581,1.46199495935322,log2_fold_induction,0.698970004336019,0.307312103470743,,0.277255081225455,0.277255081225455,0.195249205875637,10.186666488647461,dna binding
LTEA_HepaRG_NFKB1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_068810.3, , , ,,,Active,1.87479701834626,5.312548813115808,3.6079360680116648,0.557258833316759,0.117633241864225,1.35911610398198,log2_fold_induction,0.698970004336019,0.352899725592675,,0.341063462277953,0.341063462277953,0.232236374073353,10.186666488647461,dna binding
LTEA_HepaRG_NQO1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000894.1, , , ,,,Active,5.01636138349365,6.378092400562652,4.461098808361249,0.649441842486366,0.262166233436355,4.18030115381669,log2_fold_induction,1.30102999566398,0.786498700309065,,0.353057532079114,0.353057532079114,0.262346894497715,10.186666488647461,oxidoreductase
LTEA_HepaRG_PDK4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002603.1, , , ,,,Active,3.36927818752359,6.98026010961691,3.264747770799834,0.513849634008885,0.160895541360588,2.75276204755126,log2_fold_induction,0.698970004336019,0.482686624081764,,0.319704419791856,0.319704419791856,0.275331765559643,10.186666488647461,kinase
LTEA_HepaRG_PEG10_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001165908.1, , , ,,,Active,4.81142492829087,7.080335491005998,9.572511058824972,0.981025876746953,0.226515863756396,3.92432764118471,log2_fold_induction,1.69897000433602,0.679547591269188,,-0.140718697859702,-0.140718697859702,-0.384427305422246,10.186666488647461,dna binding
LTEA_HepaRG_PPP2R4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_821068.1, , , ,,,Active,1.30228461450379,4.103807507715034,2.276655651343823,0.357297347685662,0.105778565560197,1.37037460001583,log2_fold_induction,1.69897000433602,0.317335696680591,,0.295810500244776,0.295810500244776,0.238017033949959,10.186666488647461,phosphatase
LTEA_HepaRG_PTEN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000305.3, , , ,,,Active,5.10664496341461,9.455583282636352,6.1655200728243384,0.789969716005794,0.180022208775921,5.25954327205771,log2_fold_induction,1.30102999566398,0.540066626327763,,0.585915380968399,0.585915380968399,0.579951195978797,10.186666488647461,phosphatase
LTEA_HepaRG_SDHB_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002991.2, , , ,,,Active,1.86808128886749,3.1458358107441953,2.2145223199198076,0.345280061847763,0.197942232340639,2.36119903745996,log2_fold_induction,0.698970004336019,0.593826697021917,,0.303830500694149,0.303830500694149,0.225999747988971,10.186666488647461,oxidoreductase
LTEA_HepaRG_SLC22A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003048.1, , , ,,,Active,8.19924791686812,14.72875912276763,3.3541748210565516,0.525585694478044,0.185560957048395,8.95120871113803,log2_fold_induction,1.30102999566398,0.556682871145185,,0.267935533047737,0.267935533047737,0.309469330767233,10.186666488647461,transporter
LTEA_HepaRG_SLCO1B1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006437.3, , , ,,,Active,7.46842740184397,13.762725945758561,3.868005254656714,0.587487055397227,0.180885371867909,7.58034134979149,log2_fold_induction,1.30102999566398,0.542656115603727,,0.335935528976319,0.335935528976319,0.37044054982104,10.186666488647461,transporter
LTEA_HepaRG_STAT3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_644805.1, , , ,,,Active,1.28949174299751,2.8270092187980476,3.076267423022706,0.488024086426809,0.152044279919936,1.38049891161288,log2_fold_induction,0.698970004336019,0.456132839759808,,-0.12500524979963,-0.12500524979963,-1.7469304528588,10.186666488647461,dna binding
LTEA_HepaRG_SULT2A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003158.2, , , ,,,Active,17.0279203565426,30.340809298198604,5.805114895223462,0.763810819745178,0.187073897614124,13.2254546410181,log2_fold_induction,1.30102999566398,0.561221692842372,,0.216418203608032,0.216418203608032,0.40786176442684,10.186666488647461,transferase
LTEA_HepaRG_TGFA_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003227.1, , , ,,,Active,2.3224983440626,5.157497760510599,13.257868001012826,1.1224736907475,0.150104983198459,2.28603674431962,log2_fold_induction,1.69897000433602,0.450314949595377,,0.924174585744547,0.924174585744547,0.816695340156099,10.186666488647461,growth factor
LTEA_HepaRG_TGFB1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,P01137.2, , , ,,,Active,0.837428160645427,2.445805006738818,9.39065831663774,0.97269603883283,0.114131224462307,0.65727154338821,log2_fold_induction,1.69897000433602,0.342393673386921,,0.574922175436097,0.574922175436097,-1.3980077465725,10.186666488647461,growth factor
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1, , , ,,,Active,8.95035221893169,9.209863554630335,3.7620646176582144,0.575426250770816,0.323940818661091,6.83002056751943,log2_fold_induction,0.698970004336019,0.971822455983273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.353034196086931,0.353034196086931,0.343327802913737,10.186666488647461,growth factor
LTEA_HepaRG_TIMP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003245.1, , , ,,,Active,2.46399002690184,6.667623343771918,19.32674271141271,1.28615866511694,0.123181824560391,1.97489300189359,log2_fold_induction,1.69897000433602,0.369545473681173,,0.649111412540349,0.649111412540349,0.479287444151128,10.186666488647461,protease inhibitor
LTEA_HepaRG_TNFRSF1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001056.1, , , ,,,Active,9.69714759882442,18.496605473824584,8.935661307889696,0.951126699174005,0.174755445668978,8.09429000738029,log2_fold_induction,1.30102999566398,0.524266337006934,,0.488595993460439,0.488595993460439,0.59603187455807,10.186666488647461,cytokine receptor
LTEA_HepaRG_TP53_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000537.3, , , ,"[46,46]",,Active,2.26460720359401,6.155647762962827,7.276939076045387,0.861948738938483,0.122630322093241,1.86308210068652,log2_fold_induction,1.30102999566398,0.367890966279723,,0.391485186198823,0.391485186198823,0.231670926762357,10.186666488647461,dna binding
LTEA_HepaRG_UGT1A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000454.1, , , ,,,Active,4.76809172252445,7.19889719539035,3.8427183636546363,0.584638555790707,0.220778803248623,4.75908596034035,log2_fold_induction,1.30102999566398,0.662336409745869,,0.375334110367046,0.375334110367046,0.332557827879985,10.186666488647461,transferase
LTEA_HepaRG_UGT1A6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001063.2, , , ,,,Active,9.13709580318334,16.19990742918107,6.505669426922989,0.813291991667835,0.188007160804812,9.09825709134241,log2_fold_induction,1.69897000433602,0.564021482414436,,0.393818365312586,0.393818365312586,0.474600420499358,10.186666488647461,transferase
LTEA_HepaRG_XBP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005071.2, , , ,,,Active,3.20883953785028,6.196392115909368,3.6352028504612437,0.560528650237133,0.172618704445313,2.57684958151635,log2_fold_induction,0.698970004336019,0.517856113335939,,0.398155561861407,0.398155561861407,0.344037259015292,10.186666488647461,dna binding
Tanguay_ZF_120hpf_ActivityScore,"Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,100.015306380207,5.00076531901035,0.556381186243829,-0.254627563886015,2.2401450326604,99.9337347391697,percent_activity,1.47712125471966,20,"[""Noisy data"",""Noisy data""]",-0.415162744873696,-0.559214780277545,-0.509034697094323,10.199999809265137,malformation
Tanguay_ZF_120hpf_MORT_up,"Data from the assay component Tanguay_ZF_120hpf_MORT_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_MORT_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,103.212418645508,1.9576930124437584,0.5878779063512538,-0.230712861175157,10.5442904469143,102.256828469416,percent_activity,1.47712125471966,52.7214522345715,,-0.221613885316289,-0.402600024090909,-0.69320231251769,10.199999809265137,malformation
TOX21_AhR_LUC_Agonist,"Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001612.1, , , ,"[57,131,21,41,150,310,131,21,57,310,41,150]",[165],Active,110.869978677063,5.54349893385315,2.847880037658983,0.454521691397397,1.20983399992497,145.8043486283,percent_activity,1.60205999132796,20,"[""Noisy data"",""Noisy data""]",-0.273586574252009,-1.17417819641896,-0.602372090961994,20,dna binding
TOX21_AR_BLA_Antagonist_ch1,"Data from the assay component TOX21_AR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,54.8381785996199,2.4860240737427173,6.051870366672602,0.7818896167005,3.67643118576489,32.4380002904,percent_activity,1.30102999566398,22.0585871145893,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.614360693828462,0.198533931890139,-0.147408069209072,20,channel 1
TOX21_AR_BLA_Antagonist_ch2,"Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,96.9586788184299,1.8363091741311937,34.34312061105616,1.53583975508193,8.80014108229746,93.1264245955,percent_activity,1.90308998699194,52.8008464937848,,1.54554389746939,1.48247263685892,1.41655944135996,20,channel 2
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,91.5953126528185,3.5104155567683635,28.420724584977854,1.45363514604909,4.34874025461246,90.5784191788,percent_activity,1.90308998699194,26.0924415276748,,1.37721254959724,1.30458193001605,1.27120490286749,20,nuclear receptor
TOX21_AR_BLA_Antagonist_viability,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,28.463927005293,1.234385490087013,22.685144601436964,1.35574155192498,3.8431979898606,29.5412816704,percent_activity,1.60205999132796,23.0591879391636,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.43450263770339,1.334871648661,1.23645756388995,20,cell cycle
TOX21_ARE_BLA_Agonist_ch2,"Data from the assay component TOX21_ARE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,91.1888777850277,2.6969443929876884,8.835160220460134,0.946214429590468,5.63532060098133,45.6200596896,percent_activity,0.903089986991944,33.811923605888,"[""Less than 50% efficacy"",""Borderline active"",""Noisy data"",""Less than 50% efficacy"",""Borderline active"",""Noisy data""]",0.677730461854747,0.194716795871483,-0.169305576834128,20,channel 2
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2, , , ,"[61,61]",[478],Active,78.4780060400002,3.9239003020000096,6.456990208399761,0.81003012782737,2.50978290890691,50.3506496357,percent_activity,0.903089986991944,20,"[""Noisy data"",""Noisy data""]",0.585554736919779,0.340719984842443,0.350328043040965,20,dna binding
TOX21_ARE_BLA_agonist_viability,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,47.1834216392315,1.5941440333211268,10.017524297871457,1.00076040450316,4.93299441089742,42.8385823338,percent_activity,1.60205999132796,29.5979664653845,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.22507721592499,0.663350549452621,0.0540783278528195,20,cell cycle
TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability,"TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,42.8959517167593,2.144797585837965,82.2065281698818,1.91490630702401,1.8938989638513,25.9056970858,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90008220134168,1.70887590728828,1.67403956513416,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,89.5896425613384,2.7886405984616864,49.906939880810434,1.6981609412622,5.35443940025589,87.8045017115,percent_activity,1.95424250943932,32.1266364015353,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66659555405937,1.61558498767955,1.57888062120398,20,nuclear receptor
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability,"TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,33.478077821772,1.6739038910886,64.86349343500876,1.81200033531275,1.73744592492177,30.8677052268,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.83342559393645,1.72022184153273,1.69271999869292,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,"[307,111,19,23,187,117,307,19,23,111,187,117]",,Active,117.549274489365,3.9335828565165203,75.83226829042184,1.87985404677227,4.98058550254545,93.3146123209,percent_activity,1.95424250943932,29.8835130152727,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82142925184916,1.77525685573918,1.76057373299374,20,nuclear receptor
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability,"TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,35.4623553004832,1.77311776502416,56.44500324429722,1.75162550233755,3.00006271074825,34.856637487,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.765594797285,1.69307876823382,1.63234517545937,20,cell cycle
TOX21_Aromatase_Inhibition,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",NP_000094.2, , , ,"[122,123,7,153,25,122,123,7,153,25]",[964],Active,118.845915510926,4.428580832910314,75.52289668444085,1.87807863899582,4.47268624701549,85.8908235458,percent_activity,1.95424250943932,26.8361174820929,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.78199695620166,1.7173305165518,1.70674101976716,20,cyp
TOX21_Aromatase_Inhibition_viability,"TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,50.1443278033697,1.8152639007461777,87.1588340417978,1.94031141188399,4.60395205556223,27.8499949072,percent_activity,1.95424250943932,27.6237123333734,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.95139913540678,1.88780604944885,1.82103109725075,20,cell cycle
TOX21_CAR_Agonist,"Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_001070948.1, , , ,,,Active,22.3960684967106,1.11980342483553,7.577406917378075,0.879520610098405,0.83822208889671,27.8834727374,percent_activity,1.60205999132796,20,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",1.10651408413666,0.658331499337256,0.644469507999812,20,nuclear receptor
TOX21_CAR_Agonist_viabillity,"TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,46.3693854069985,2.318469270349925,81.43858675190432,1.91083022850969,2.77710640921686,31.7647788847,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.89582147694979,1.82839214648336,1.79154991447029,20,cell cycle
TOX21_CAR_Antagonist_viability,"TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,43.6134768967206,2.18067384483603,86.89131341702293,1.9389763619076,2.40485484020376,24.9834418525,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.9299601190697,1.85111657605887,1.81969604794518,20,cell cycle
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,57.5993403734466,2.87996701867233,51.06005382425375,1.70808126827403,2.57636017956492,53.8112495937,percent_activity,1.95424250943932,20,,1.64893485420788,1.53338994103968,1.50220866138219,20,cell cycle
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,121.087028074889,5.0451628972443645,71.34017591383213,1.85333417590663,4.0001030208237,93.8798340701,percent_activity,1.95424250943932,24.0006181249422,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.7430983819839,1.6792305407652,1.68001824475145,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,108.173606090199,5.015143552592805,68.42010785201101,1.83518375443683,3.59489896137582,97.0466130856,percent_activity,1.95424250943932,21.5693937682549,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.75972096573543,1.71572081576036,1.71590319724164,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,111.572727289068,4.258173508406283,77.85719575179301,1.89129875731363,4.36700254498032,85.4219185326,percent_activity,1.95424250943932,26.2020152698819,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.8271761442462,1.78179647507811,1.7720168865525,20,cell cycle
TOX21_ERa_BLA_Antagonist_ch1,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,52.7502991418348,2.197598285047036,13.291697210782072,1.12358043934875,4.00060219534206,52.685515013,percent_activity,1.47712125471966,24.0036131720524,,1.10399350993014,0.990802262312885,0.884908462264269,20,channel 1
TOX21_ERa_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,75.2763466335054,1.9333151971977196,35.20841415807019,1.54664646420936,6.48940110253932,54.1847857634,percent_activity,1.60205999132796,38.9364066152359,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55039292408477,1.48947497003619,1.42736608478939,20,channel 2
TOX21_ERa_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,79.1505456778245,3.957527283891225,19.336601392979965,1.28638014472226,3.3294568553358,65.1904857271,percent_activity,1.47712125471966,20,,1.12783278201046,1.00345182884112,0.965115770622113,20,nuclear receptor
TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability,"TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,63.2570848075585,3.162854240377925,69.78465825117507,1.84375995601576,1.88022155075055,38.8648441019,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.67654946205914,1.34006509823666,1.3675020986543,20,cell cycle
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_000116.2, , , ,,,Active,92.1580704656761,3.911745918044295,15.793668234975563,1.19848301089417,3.92655318948354,88.2923577155,percent_activity,1.95424250943932,23.5593191369012,,0.926304406512551,0.709423281150802,0.638917245954705,20,nuclear receptor
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,34.9360158686874,1.4260837843963141,27.490164446393514,1.43917733780446,4.08297841624554,35.298558426,percent_activity,1.69897000433602,24.4978704974732,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.48549061681154,1.40571719152053,1.31989662540501,20,nuclear receptor
TOX21_ERb_BLA_Agonist_viability,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,47.0631573518356,2.290202634096761,2.383960546853095,0.377299063809065,3.42496311979521,24.2104560637,percent_activity,0.602059991327962,20.5497787187713,"[""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Borderline active"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Borderline active""]",0.36334033337904,0.30742435636335,0.256927982859308,20,cell cycle
TOX21_ERb_BLA_Antagonist_ch1,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,31.545142719321,1.0824939629788033,3.8104014694061674,0.580970735980667,4.85686199310144,35.7127941141,percent_activity,1.69897000433602,29.1411719586086,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.03651134074627,0.55308893475256,0.179803236255085,20,channel 1
TOX21_ERb_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,78.8710847202077,2.1559882420974144,16.37141222311986,1.21408614393573,6.09705587907717,66.8306525478,percent_activity,1.30102999566398,36.582335274463,,1.20621696676964,1.14907523778994,1.09480582919288,20,channel 2
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1, , , ,,,Active,59.8827431574127,2.4691330260875892,8.425290448350287,0.925584881405874,4.04208970819059,62.3207555257,percent_activity,1.60205999132796,24.2525382491435,,0.904702239579195,0.851171744209298,0.806304558563575,20,nuclear receptor
TOX21_ERb_BLA_Antagonist_viability,"TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,33.5519124989799,1.5924050737031001,2.9054702394869873,0.463216431351879,3.51166013525229,26.1709245289,percent_activity,0.602059991327962,21.0699608115137,"[""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy""]",0.491639197561285,0.42078955056318,0.343935646023651,20,cell cycle
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3, , , ,,,Active,78.2412866789173,3.7026864987760586,25.95829050131543,1.41427608834823,3.52182515338437,76.4736685089,percent_activity,1.95424250943932,21.1309509203062,,1.34621331247829,1.28714268718987,1.26386144031647,20,nuclear receptor
TOX21_ERR_viability,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,28.2372109355666,1.41186054677833,77.36056999478943,1.88851966098032,2.25399102610353,21.7801959184,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.93667588708739,1.82578659271574,1.76923934712169,20,cell cycle
TOX21_FXR_BLA_agonist_viability,"TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,58.3507293759751,1.0908698633569787,2.1840688036315252,0.339266315610922,8.9150153371503,61.3627963164,percent_activity,0.903089986991944,53.4900920229018,"[""Cell viability assay fit with gnls winning model"",""Borderline active"",""Cell viability assay fit with gnls winning model"",""Borderline active""]",0.518109165684079,0.326814069792754,0.175419631182071,20,cell cycle
TOX21_FXR_BLA_Antagonist_ch1,"Data from the assay component TOX21_FXR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,39.7378521220527,1.8956474057364952,66.14156473572908,1.82047446496617,3.49378019015214,23.8901916666,percent_activity,1.90308998699194,20.9626811409128,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.85313309127788,1.51628492342983,1.16935989632215,20,channel 1
TOX21_FXR_BLA_Antagonist_ch2,"Data from the assay component TOX21_FXR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,40.2453859260389,1.0035780597091433,22.988179111586717,1.36150457226498,6.68364982286526,42.088824706,percent_activity,1.90308998699194,40.1018989371916,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.8923617262636,1.36083256924273,1.15443446274501,20,channel 2
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,54.0322458980839,2.701612294904195,23.704993881112607,1.37483984755207,2.78938673282934,52.817245011,percent_activity,1.90308998699194,20,,1.28188660449309,1.07811791700119,0.99062560657118,20,nuclear receptor
TOX21_FXR_BLA_antagonist_viability,"TOX21_FXR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,45.6847807609305,1.1166794855540159,3.0501471302984045,0.484320788965005,6.81854571998712,46.3324261291,percent_activity,0.845098040014257,40.9112743199227,"[""Borderline active"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model""]",0.603309596568634,0.472703889910804,0.362623565264141,20,cell cycle
TOX21_GR_BLA_Agonist_ch1,"Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,26.9411411653734,1.2332973877506612,17.317359577500692,1.23848167472875,3.6408008634627,23.3312655228,percent_activity,1.90308998699194,21.8448051807762,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",1.9101838020976,1.06174917049762,0.224438424770758,20,channel 1
TOX21_GR_BLA_Antagonist_ch2,"Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,94.9616568209863,1.9048864550311064,15.945953462846882,1.20265049230103,8.30860168158384,95.6731236574,percent_activity,1.90308998699194,49.851610089503,,1.21791019009551,1.04491651464746,0.8671788604883,20,channel 2
TOX21_GR_BLA_Antagonist_ratio,"Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000167.1, , , ,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,66.0208997704191,1.734496940141384,19.977324873809682,1.30053733222199,6.34390470252021,64.9119538215,percent_activity,1.90308998699194,38.0634282151213,,1.32571627696404,1.22678732059729,1.12124610184571,20,nuclear receptor
TOX21_GR_BLA_Antagonist_viability,"TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,64.6849745346975,1.6625184851473298,39.73423625428594,1.59916486970633,6.48463712459766,47.1618445405,percent_activity,1.90308998699194,38.907822747586,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.73615740279078,1.31841770146981,0.868053927599475,20,cell cycle
TOX21_H2AX_HTRF_CHO_viability,"TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,54.2371569786264,2.71185784893132,66.10539029634332,1.82023687371427,2.15763115046871,51.5732033437,percent_activity,2.30102999566398,20,,1.74886058506528,1.55486847689396,1.52850363073369,20,cell cycle
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,30.5547903424343,1.527739517121715,1.2001484056866905,0.0792349525357254,3.0508964104962,22.7438952326,percent_activity,0.301029995663981,20,"[""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Borderline active""]",0.116030575507599,0.0303331237294711,-0.0472579466146035,20,cell cycle
TOX21_HSE_BLA_agonist_ch1,"Data from the assay component TOX21_HSE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,21.1228687607175,1.056143438035875,32.93553245568156,1.51766468890081,3.14273554940163,21.07082106,percent_activity,1.90308998699194,20,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.67400231368708,1.50596986567648,1.39838437501674,20,channel 1
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,95.6377050988034,2.473590519411008,1.962447086330864,0.292797955646932,6.44391923052108,102.7872481058,percent_activity,1.30102999566398,38.6635153831265,,0.222162470966043,0.0426505493201901,-0.107514763498542,20,cell morphology
TOX21_MMP_viability,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,32.8306414248652,1.64153207124326,13.008690434695533,1.11423357898961,3.32276785161468,27.3126616403,percent_activity,1.60205999132796,20,"[""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy""]",1.32748279790083,0.715460039236006,0.0586793113484134,20,cell cycle
TOX21_p53_BLA_p1_ch1,"Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,31.2474562957316,1.5623728147865799,10.10532532050112,1.00455029930845,3.00976293237186,28.5706970863,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.16389589887841,0.755274673317685,0.396273750273191,20,channel 1
TOX21_p53_BLA_p1_ch2,"Data from the assay component TOX21_p53_BLA_p1_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,30.0699045267546,1.50349522633773,3.4482139655855115,0.537594206453726,1.71156233629626,29.3582867397,percent_activity,0.903089986991944,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.623447554158215,0.339875533157673,0.262682670758488,20,channel 2
TOX21_p53_BLA_p1_ratio,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,40.0082620095962,2.0004131004798102,4.171425940792696,0.620284537554126,1.19928273802848,31.205395574,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.620193086402221,0.107796306647936,0.13376798892155,20,dna binding
TOX21_p53_BLA_p2_ch1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,22.0559067687865,1.102795338439325,8.887946586584777,0.948801435984432,2.8966141715805,23.5815024091,percent_activity,1.30102999566398,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.07230475886135,0.92542748105622,0.829521121852417,20,channel 1
TOX21_p53_BLA_p2_ch2,"Data from the assay component TOX21_p53_BLA_p2_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,55.789648135917,2.78948240679585,6.603207151328927,0.819754921878175,1.60204778429955,53.3869744685,percent_activity,1.30102999566398,20,,0.72938831170954,0.453023960475968,0.478550724802504,20,channel 2
TOX21_p53_BLA_p2_ratio,"Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,45.160025757565,2.2580012878782503,2.5433987211662035,0.405414448586448,0.95929146331389,45.4722407167,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.380542335257615,0.114206982305339,0.167314836539209,20,dna binding
TOX21_p53_BLA_p3_ch1,"Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,26.2055868711961,1.275773254922335,1.363524782541662,0.134663035804074,3.42349065166122,28.1002170566,percent_activity,1.95424250943932,20.5409439099673,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.499241931166154,0.0103461419612881,-0.487194170257677,20,channel 1
TOX21_p53_BLA_p3_ch2,"Data from the assay component TOX21_p53_BLA_p3_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,39.5191914828315,1.9759595741415752,3.8454033864870647,0.584941904432993,1.46618228323455,44.7502694608,percent_activity,0.954242509439325,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.588716625147948,0.26267667919407,0.244107249662997,20,channel 2
TOX21_p53_BLA_p3_ratio,"Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter,  gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,31.5802311144725,1.579011555723625,2.431127501725467,0.385807736236893,0.8227628069073,36.0289405777,percent_activity,0.903089986991944,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.459510270228504,0.052976155674553,0.0894474039218113,20,dna binding
TOX21_p53_BLA_p4_ch1,"Data from the assay component TOX21_p53_BLA_p4_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,37.45822686481,1.8729113432405,9.056096557829056,0.956941044399495,2.74402988187153,33.9663548451,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.02968514885457,0.278839054632991,-0.218997935152911,20,channel 1
TOX21_p53_BLA_p4_ch2,"Data from the assay component TOX21_p53_BLA_p4_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,37.3994468081399,1.869972340406995,11.335538462727182,1.05444215488484,1.34760150021231,31.1662056967,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.07681755535634,0.715452219155703,0.701492070249172,20,channel 2
TOX21_p53_BLA_p4_ratio,"Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,35.2466118371515,1.762330591857575,3.845730602028208,0.584978858126482,1.02079986237957,29.3721765338,percent_activity,0.903089986991944,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.630743166373936,0.188294002227189,0.21444187411157,20,dna binding
TOX21_p53_BLA_p5_ch1,"Data from the assay component TOX21_p53_BLA_p5_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,31.6094437034762,1.3482195522079952,5.041268291551307,0.70253981079656,3.90755393557242,35.781283127,percent_activity,1.60205999132796,23.4453236134345,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.912466808092682,0.597363313191182,0.265297328652638,20,channel 1
TOX21_p53_BLA_p5_ch2,"Data from the assay component TOX21_p53_BLA_p5_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,54.9559822846281,2.747799114231405,9.113297473306497,0.95967554660478,1.61374125094707,45.7966519332,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.838773028461715,0.453607019517535,0.483904992938766,20,channel 2
TOX21_p53_BLA_p5_ratio,"Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,50.5851533641254,2.5292576682062697,8.740841511701474,0.941553245711702,1.35224934572532,43.7928411209,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.85942565520321,0.469864370754274,0.516741045117678,20,dna binding
TOX21_PGC_ERR_Antagonist,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_004442.3, , , ,,,Active,125.905289096487,3.776278087202864,71.21470422755286,1.85256967489476,5.55685104879492,77.3048542546,percent_activity,1.95424250943932,33.3411062927695,,1.46470238064568,1.13850997999224,1.01795779255688,20,nuclear receptor
TOX21_PGC_ERR_viability,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,38.1476989396386,1.9073849469819302,64.38641318706917,1.80879423226014,2.5904653717656,30.9830178693,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.82092504992096,1.63864151138038,1.53454233604513,20,cell cycle
TOX21_PPARd_BLA_agonist_ch2,"Data from the assay component TOX21_PPARd_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,34.0749572879285,1.703747864396425,29.88734222050028,1.47548729642799,2.08611861938907,25.3114423587,percent_activity,1.60205999132796,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.5218949524656,1.27844745191328,1.18525716424238,20,channel 2
TOX21_PPARd_BLA_Agonist_viability,"TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,45.9033248183146,1.3766509424697393,1.7322779578738958,0.238617579301089,5.55736672264977,40.5996741802,percent_activity,0.845098040014257,33.3442003358986,"[""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy""]",0.38876851776136,0.152273120932636,-0.0992593489455228,20,cell cycle
TOX21_PPARd_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_006229.1, , , ,"[36,36]",,Active,54.2802870584174,1.4957825814351111,53.049868967752744,1.72468431553892,6.04814805441609,43.7331514698,percent_activity,1.90308998699194,36.2888883264965,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.83642599143343,1.61496479235373,1.37474798367267,20,nuclear receptor
TOX21_PPARg_BLA_Antagonist_ch1,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,56.8296793761793,2.101354816450265,85.87432810191108,1.93386335207315,4.5073840720356,28.5656477644,percent_activity,1.30102999566398,27.0443044322136,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.92045020160646,1.77214078967665,1.62858702906409,20,channel 1
TOX21_PPARg_BLA_Antagonist_ch2,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,136.646908915809,1.488791150541627,1.1625941203003027,0.0654281222264326,15.2972999678404,138.146541305,percent_activity,1.60205999132796,91.7837998070424,,0.241723390251698,-0.102507038503188,-0.475713937088024,20,channel 2
TOX21_PPARg_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,"[34,36,58,72,163,72,36,58,34,163]",,Active,88.0525592591704,2.447116667731641,0.6567011052570482,-0.182632252774941,5.9970277415496,90.8593279369,percent_activity,0.903089986991944,35.9821664492976,,-0.269427223595897,-0.501912786059858,-0.698654814132054,20,nuclear receptor
TOX21_PR_BLA_Agonist_ch1,"Data from the assay component TOX21_PR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,33.7523591749136,1.329097865732358,17.245943961953014,1.23668697059367,4.23248982701454,35.926463302,percent_activity,1.60205999132796,25.3949389620872,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.29702135480846,1.20923248855115,1.11740662243202,20,channel 1
TOX21_PR_BLA_Agonist_viability,"TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,67.4073597169944,2.0278814700231336,2.9634378212248236,0.471795819315126,5.54004764031117,51.0486906117,percent_activity,0.602059991327962,33.240285841867,"[""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model""]",0.464108544722457,0.159542910116552,-0.142413466596625,20,cell cycle
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,70.9638478330664,1.708120258988526,17.27144172460901,1.23732859158647,6.92416585421295,76.4541653758,percent_activity,1.95424250943932,41.5449951252777,,1.25872749084731,1.18263104858347,1.10109980178378,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,41.3132318356115,2.0656615917805747,20.40567919791454,1.30975105473278,2.51198214229767,41.7749829431,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.3062986405067,1.22831518577535,1.1904707391275,20,nuclear receptor
TOX21_PR_BLA_Antagonist_viability,"TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,62.8119483372175,1.9103926371702613,3.631723463827223,0.560112771923337,5.47984631667627,48.4659858976,percent_activity,0.954242509439325,32.8790779000576,"[""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy""]",0.573571322766618,0.411446102667403,0.245118330031454,20,cell cycle
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,45.4500857325149,2.272504286625745,27.09755815119629,1.43293015695406,1.80636679455099,44.2487673542,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.41984774949461,1.32437151553221,1.31364983680427,20,nuclear receptor
TOX21_PXR_viability,"The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,57.1476560044757,2.857382800223785,47.14291594484082,1.67341644156523,2.43196946437473,56.7755868726,percent_activity,1.95424250943932,20,,1.63980376388038,1.56909131391997,1.55413612703751,20,cell cycle
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2, , , ,,,Active,68.7109793748502,1.3186958780896865,45.71025416487525,1.66001363612407,8.68420845631059,71.7289497438,percent_activity,1.95424250943932,52.1052507378635,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72209159078248,1.63324455667156,1.54073330232844,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist_viability,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,26.954059091753,1.34770295458765,40.42942921680074,1.6066976100019,3.0881472477345,20.1460248482,percent_activity,1.95424250943932,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",2.03202960240067,1.34628437527609,0.722047910561347,20,cell cycle
TOX21_RT_HEK293_FLO_08hr_viability,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,28.3957968968428,1.205733191424018,33.00831728327561,1.51862338518414,3.92510785122456,23.6634454569,percent_activity,1.60205999132796,23.5506471073474,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.60446033984645,1.49991456780619,1.39934307143385,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,28.3127513700523,1.16615135004921,35.11428984312848,1.54548388960182,4.04646609105207,28.0196914428,percent_activity,1.90308998699194,24.2787965463124,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.68621684521009,1.52298764497279,1.37320161093588,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,26.8976737167739,1.1157965882040486,34.69252796676323,1.5402359470607,4.0177086637968,26.8621482164,percent_activity,1.90308998699194,24.1062519827808,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.65727397747744,1.5289275377204,1.42095563249011,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,33.8389396692455,1.3792016641287508,36.97223970508447,1.56787576006991,4.08919407864135,33.1077382805,percent_activity,1.90308998699194,24.5351644718481,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.65312986643073,1.51825362423796,1.37469755450782,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,40.0976456523508,1.596091434658489,35.89409919923095,1.55502305872185,4.18706647811088,40.0289487507,percent_activity,1.90308998699194,25.1223988686653,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.58310895073478,1.51241345794115,1.43574273573849,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,36.675535747529,1.472595270901157,25.605181121231478,1.40832785221389,4.15089564121323,30.5629465401,percent_activity,1.60205999132796,24.9053738472794,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.51060794821031,1.31753181125191,1.1084912050552,20,cell cycle
TOX21_RXR_BLA_Agonist_ch2,"Data from the assay component TOX21_RXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,57.9847007041511,1.9706768713371252,19.128762253529207,1.28168686945996,4.90395808901334,34.417300896,percent_activity,0.903089986991944,29.42374853408,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.30431697804766,0.461337609889709,-0.389034967858762,20,channel 2
TOX21_RXR_BLA_Agonist_viability,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,75.9276282521176,2.8511791863771854,3.536605912306626,0.548586668622786,4.43837580224682,73.6510625604,percent_activity,0.903089986991944,26.6302548134809,"[""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model""]",0.48714525126717,0.394134363270567,0.329366813805624,20,cell cycle
TOX21_SBE_BLA_Antagonist_ch2,"Data from the assay component TOX21_SBE_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,79.5193157899627,2.1673441838499383,75.90142357107007,1.88024992139301,6.11495829646443,44.907202517,percent_activity,1.90308998699194,36.6897497787866,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.87180977064962,1.81455444676273,1.76039754629537,20,channel 2
TOX21_SBE_BLA_Antagonist_ratio,"Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",NP_005891.1, , , ,,,Active,72.6293326380498,3.5598376697194642,70.93153937583682,1.85083938512947,3.40040470833105,51.297388862,percent_activity,1.90308998699194,20.4024282499863,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79981282675615,1.75249832736094,1.73155905938852,20,growth factor receptor
TOX21_SHH_3T3_GLI3_Antagonist,"Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",, , , ,,,Active,91.1151755086465,2.061324912206832,16.376233906143884,1.21421403284339,7.36703975915985,82.3897363063,percent_activity,1.60205999132796,44.2022385549591,,1.18134602256632,0.585392807901581,0.000827399820249264,20,dna binding
TOX21_TRHR_HEK293_Agonist,"TOX21_TRHR_HEK293_Agonist  used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,36.0563387189172,1.8028169359458601,52.380705005987316,1.71917133941471,0.23532099546207,25.0408151138,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.79107108277926,0.43800943153409,0.999866533269313,20,gpcr
TOX21_TRHR_HEK293_Antagonist,"TOX21_TRHR_HEK293_Antagonist  used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,71.679088132329,3.58395440661645,189.73665024205914,2.27815122894082,2.87526712790688,54.51891415,percent_activity,1.77815125038364,20,,1.20391221101743,0.027173571080549,-0.208199034191537,20,gpcr
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2", , , ,,,Active,119.974783842324,5.347246059465343,8.544358384276281,0.931679456099436,3.73945711206963,120.0513349514,percent_activity,1.95424250943932,22.4367426724178,,0.631860276999009,0.468231410277817,0.483397052226146,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,85.0065600756687,2.1211684952889223,34.46937963095517,1.5374334671829,6.67922423139783,83.343338052,percent_activity,1.95424250943932,40.075345388387,,1.52359962304211,1.39515430406103,1.27166727477539,20,cell cycle
TOX21_VDR_BLA_Antagonist_ch1,"Data from the assay component TOX21_VDR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,33.8204521138928,1.212275080988343,68.69214440476107,1.836907074225,4.64972192151852,27.9232615685,percent_activity,1.90308998699194,27.8983315291111,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.92108341195542,1.8176885168628,1.71757187553887,20,channel 1
TOX21_VDR_BLA_antagonist_viability,"TOX21_VDR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,61.7699054640081,1.3677413968206409,3.8250146415698443,0.582633101905537,7.52699616165189,56.0605393504,percent_activity,0.903089986991944,45.1619769699113,"[""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active""]",0.637017958726091,0.552662759487845,0.463182189448942,20,cell cycle